## Yi Wang

1234 Steelwood Road Apt 421, Columbus, Ohio-43212 917-868-8035 wang.14000@osu.edu or yw2316@nyu.edu

EDUCATION	
New York University, New York	
• M.S. in Biology	May.2017
• Overall GPA: 3.8/4.0;	
Fudan University, Shanghai, China	
B.S. in Biological Technology	Jun.2015
• Overall GPA: 3.3/4.0;	
Experience	
Memorial Sloan Kettering Cancer Center, New York	
Dr. Liang Deng's laboratory, Senior Research Technician	Apr.2016-
Aug.2020	-
The Rockefeller University, New York	
Dr. Charles M. Rice's Laboratory, Guest Researcher	Oct.2018-
Aug.2020	

## **Research Projects**

Intratumoral delivery of engineered Modified Vaccinia Virus Ankara (MVA) expressing Flt3L and OX40L for "in situ" therapeutic cancer vaccination: Memorial Sloan Kettering Cancer Center, Sept. 2016-Aug. 2020

- Generated recombinant MVA $\Delta$ E5R recombinant virus expressing Flt3L and OX40L.
- Evaluated its anti-tumor efficacy *in vivo* by intratumoral injection of virus in different murine tumor models including B16-F10 melanoma, AT3 and MMTV-PyMT breast cancer model.
- Evaluated the anti-tumor immunity of combination therapy of intratumoral injection of virus and systemic delivery of immune checkpoint blockades antibodies in murine tumor models.
- Researched on the mechanism of tumor infiltrating T cell activation and regulatory T cells reduction induced by intratumoral injection of MVA∆E5R-hFlt3L-OX40L.

# Screening and validation of vaccinia inhibitors of the cytosolic DNA sensing pathway mediated by cGAS/STING: *Memorial Sloan Kettering Cancer Center*, Sept. 2017- Aug. 2020

- Identified 6 candidate vaccinia viral genes that inhibit cGAS-STING-IFNβ pathway by performing a dual luciferase-based screen of 72 vaccinia virus early genes
- Discovered vaccinia E5 protein as a major inhibitor of the cytosolic DNA sensor cGAS.
- Generated and purified recombinant viral proteins for biochemical assays and antibody production.

# **Developing recombinant MVA-based immunotherapy for chronic viral hepatitis:** *Deng lab MSKCC/Rice lab at the Rockefeller University, Nov. 2018-Aug. 2020*

- Evaluated the therapeutic efficacy of combination of intravenous delivery of MVA $\Delta$ E5R-hFlt3L-OX40L and immune checkpoint blockade antibodies in mouse chronic hepacivirus infection model.
- Investigated the immune microenvironment of chronically virus-infected liver before and after MVAΔE5R-hFlt3L-OX40L treatment.

#### **Functional Analysis and Mechanism of Inhibition of Hepatoma Cell Metastasis by BRMS1 through Regulating SCIN Gene**: Fudan University, Sept. 2013- May. 2015

- Researched on regulation of *SCIN* expression by BRMS1 by siRNA, qPCR.
- Analysis on activity of hepatoma cells regulated by SCIN gene by FACS analysis, Transwell assay, Invasion

assay and *in vivo* analysis.

• Researched on effect of BRMS1 on *SCIN* gene expression by regulation of its promoter by Luciferase assay and RNA-seq.

#### **Publications**

- Yang N, Luna JM, Dai P, **Wang Y**, Rice CM & Deng L. (2020). Lung type II alveolar epithelial cells collaborate with CCR2<sup>+</sup> inflammatory monocytes in host defense against an acute vaccinia infection in the lungs. *BioRxiv*.
- Qiao X, Zhou Y, Xie W, **Wang Y**, Zhang Y, Tian T, ... & Qiao S. (2018). Scinderin is a novel transcriptional target of BRMS1 involved in regulation of hepatocellular carcinoma cell apoptosis. *American journal of cancer research*, 8(6), 1008.

### <u>Skills</u>

- Lab Skill: DNA/RNA extraction, PCR/qPCR, protein purification, molecular cloning, immunoblot, Flow Cytometry, virus purification, recombinant virus generation, mouse handling
- Computer Skill: Linux, Python, R, MySQL

### SCIENTIFIC PRESENTATIONS

- 2019 The Society for Immunotherapy of Cancer (SITC) Conference, National Harbor, Maryland Yang N, Wang Y, Dai P, Shuman S and Deng L. Improving the immunogenicity of modified vaccinia virus Ankara (MVA) vaccine vector by deletion of the vaccinia E5R gene encoding a dominant cGAS inhibitor. (Poster presentation)
- 2019 CRI-CIMT-EATI-AACR 5<sup>th</sup> International Cancer Immunotherapy Conference, Paris, France Yang N, Wang Y, Wang W, Mazo G, Dai P, Wang J, Yan W, Choi J, Shuman S, Merghoub T, Wolchok JD and Deng L. Dramatically Improving Vaccinia Virus-Based Cancer Immunotherapy by Deleting E5R, Which Encodes a Dominant Viral Inhibitor of cGAS. (Poster presentation)
- 2019 Society for Investigative Dermatology Conference, Chicago Yang N<sup>#</sup>, Wang Y<sup>#</sup>, Yan W, Wang J, Choi J, Shuman S, Merghoub T, Wolchok JD and Deng L. Rational Design of Recombinant Modified Vaccinia Virus Ankara for Cancer Immunotherapy. (Oral presentation)
- 2018 CRI-CIMT-EATI-AACR 4<sup>th</sup> International Cancer Immunotherapy Conference, New York Yang N<sup>#</sup>, Wang Y<sup>#</sup>, Yan W, Wang J, Choi J, Shuman S, Merghoub T, Wolchok JD and Deng L. Intratumoral delivery of engineered modified vaccinia virus Ankara expressing Flt3L and OX40L for "in situ" therapeutic cancer vaccination. (Oral presentation)

# • 2018 International Investigative Dermatology Conference, Orlando

Dai P, Meyer C, **Wang Y**, Shaw K, Anderson L, Shuman S, Tushl T and Deng L. The cytosolic dsRNAsensing pathway mediated by MDA5/MAVS/IRF3 is critical for the induction of type I and III IFNs after viral infection of skin keratinocytes. (Poster presentation)

#### Patents

• 2018 Co-inventor on patent application. Recombinant modified vaccinia Ankara virus and vaccinia virus expressing human Flt3L and OX40L for cancer immunotherapy.

#### **Additional Information**

#### Awards and Honors

- University Scholarship for Academic Excellence, Fudan University 2012-2014
- Professional Scholarship, School of Life Science, Fudan University 2012-2014

#### Volunteer

• Volunteering teaching in Qiu Yunfang Elementary School, Jiangxi Province, China Jun.-Jul. 2013

Jul.-Aug. 2012

• Volunteering teaching in Naqu Elementary School, Tibet, China

> Responsible for curriculum design, teaching and extracurricular activities organization.